Prenatal exposure to metronidazole and risk of childhood cancer: A retrospective cohort study of children younger than 5 years

Cancer

Volumn 83, Issue 7, 1998, Pages 1461-1468

  Thapa, Purushottam B ^a   Whitlock, James A ^a   Brockman Worrell, Kelly G ^a   Gideon, Patricia ^a   Mitchel Jr , Edward F ^a   Roberson, Paula ^b,d   Pais, Ray ^c   Ray, Wayne A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c East Tennessee Children's Hospital   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Childhood cancer; Fetal exposure; Metronidazole; Neuroblastoma

Indexed keywords

METRONIDAZOLE;

ARTICLE; CANCER RISK; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; FEMALE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRENATAL EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; CARCINOGENS; CHILD, PRESCHOOL; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; METRONIDAZOLE; NEOPLASMS; NEUROBLASTOMA; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032189453     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981001)83:7<1461::AID-CNCR25>3.0.CO;2-1     Document Type: Article

References (50)

1. Webster LT. Drugs used in the chemotherapy of protozoal infections: amebiasis, giardiasis, the trichomoniasis. In: Gilman AG, Rail TW, Nies AS, Taylor P, editors. The Pharmacological basis of therapeutics. 8th edition. New York: Pergamon Press, Inc., 1991:999-1007.
2. Roe FJC. Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential. Surgery 1983;93:158-64.
3. Rustia M, Shubik P. Induction of lung tumors and malignant lymphomas in mice by metronidazole. J Natl Cancer Inst 1972;48:721-9.
4. Cavaliere A, Bacci M, Amorosi A, Gaudio MD, Vitali R. Induction of lung tumors and lymphomas in BALB/c mice by metronidazole. Tumori 1983;69:379-82.
5. Chacko M, Bhide SV. Carcinogenicity, perinatal carcinogenicity and teratogenicity of low dose metronidazole (MNZ) in Swiss mice. J Cancer Res Clin Oncol 1986;112:135-40.
6. Sloan DA, Fleiszer DM, Richards GK, Murray D, Brown RA. Increased incidence of experimental colon cancer associated with long-term metronidazole therapy. Am J Surg 1983; 145:66-70.
7. A Kareem AM, Fleiszer DM, Richards GK, Senterman MK, Brown RA. Effect of long term metronidazole (MTZ) therapy on experimental colon cancer in rats. J Surg Res 1984;36: 547-52.
8. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC. Cancer after exposure to metronidazole. Mayo Clin Proc 1988;63:147-53.
9. Friedman GD, Selby JV. Metronidazole and cancer. JAMA 1989;261:866.
10. Danielson DA, Hannan MT, Jick H. Metronidazole and cancer. JAAM 1982;247:2498-9.
11. Krause JK, Ayuyang HQ, Ellis LD. Occurrence of three cases of carcinoma in individuals with Crohn's disease treated with metronidazole. Am J Gastroenterol 1982;80:978-82.
12. Carvajal A, Sanchez A, Hurtarte G. Metronidazole during pregnancy. Int J Gynaecol Obstet 1995;48:323-4.
13. Piper JM, Mitchel EF Jr. Prenatal exposure to prescribed drugs in Tennessee Medicaid, 1983-88. Paediatr Perinat Epidemiol 1991;5:402-9.
14. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993;82: 348-52.
15. Piper JM, Ray WA, Griffin MR, Fought R, Daugherty JR, Mitchel E Jr. Methodological issues in evaluating expanded Medicaid coverage for pregnant women. Am J Epidemiol 1990;132:561-71.
16. SAS Institute Inc., SAS Technical Report P-243. SAS/STAT software: the GENMOD procedure. Release 6.09. 1993;1-88. Cary, NC: SAS Institute Inc., 1993.
17. U. S. Department of Health and Human Services. Cancer statistics review 1973-1987. Washington, DC: U. S. Department of Health and Human Services, 1990 NIH Pub No. 90-2789.
18. Rein MF, Muller M. Trichomona vaginalis. In: Holmes KK, Mardh P, Sparling PF, Wiesner PJ, editors. Sexually transmitted diseases. New York: McGraw-Hill Book Company, 1989:525-36.
19. Walsh JH, Peterson WL. Drug therapy: the treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984-91.
20. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young females. N Engl J Med 1971;284: 878-81.
21. Gilman EA, Wilson LM, Kneale GW, Waterhouse JA. Childhood cancers and their association with pregnancy drugs and illnesses. Paediatr Perinat Epidemiol 1989;3:66-94.
22. Golding J, Paterson M, Kinlen LJ. Factors associated with childhood cancer in a national cohort study. Br J Cancer 1990;62:304-8.
23. McKinney PA, Cartwright RA, Stiller CA, Hopton PA, Mann JR, Birch JM, et al. Inter-regional epidemiological study of childhood cancer (IRESCC): childhood cancer and the consumption of Debendox and related drugs in pregnancy. Br J Cancer 1985;52:923-9.
24. Sanders BM, Draper GJ. Childhood cancer and drugs in pregnancy. BMJ 1979;1:718-9.
25. Robison LL, Buckley JD, Daigle AE, Wells R, Benjamin D, Arthur DC, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. Cancer 1989; 63:1901-11.
26. Gold E, Gordis L. Increased risk of brain tumors in children exposed to barbiturates. J Natl Cancer Inst 1978;61:1031-4.
27. Preston-Martin S, Yu MC, Benton B, Henderson BE. N-nitroso compounds and childhood brain tumors: a case control study. Cancer Res 1982;42:5240-5.
28. Birch JM, Hartley AL, Teare MD, Blair V, McKinney PA, Mann JR, et al. The inter-regional epidemiological study of childhood cancer (IRESCO): case control study of children with central nervous system tumors. Br J Neurosurg 1990;4: 17-26.
29. McCredie M, Maisonneuve P, Boyle P. Antenatal risk factors for malignant brain tumors in New South Wales children. Int J Cancer 1994;56:6-10.
30. Goldhaber MK, Selby JB, Hiatt RV, Quesenberry CP. Exposure to barbiturates in utero and during childhood and risk of intracranial and spinal cord tumors. Cancer Res 1990;50: 4600-3.
31. Carozza SE, Olshan AF, Faustman EF, Gula MJ, Kolonel LN, Austin DF, et al. Maternal exposure to N-nitrosatable drugs as a risk factor for childhood brain tumors. Int J Epidemiol 1995;24:308-12.
32. Bunin GR, Buckley JD, Boesel CP, Rorke LB, Meadows AT. Risk factors for astrocytic glioma and primitive neuroecto-dermal tumor of the brain in young children: a report from the Children's Cancer Group. Cancer Epidemiol Biornarkers Prev 1994;3:197-204.
33. Kramer S, Ward E, Meadows AT, Malone KE. Medical and drug risk factors associated with neuroblastoma: a case control study. J Natl Cancer Inst 1987;78:797-804.
34. Schwartzbaum JA. Influence of the mother's prenatal drug consumption on risk of neuroblastoma in the child. Am J Epidemiol 1992;135:1358-67.
35. Ross JA,Davies SM, Potter JD, Robison LL. Epidemiology of childhood leukemia, with a focus on infants. Epidemiol Rev 1994;16:(2)243-72.
36. Shu XO, Gao YT, Brinton LA, Linet MS, Tu JT, Zheng W, et al. A population-based case-control study of childhood leukemia in Shanghai. Cancer 1988;62:635-44.
37. Hayes FA, Smith EI. Management of common cancers of childhood: neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: J.B. Lippincott, 1989:607-22.
38. Al-Shammri S, Guberman A, Hsu E. Neuroblastoma and fetal exposure to pheytoin in a child without dysmorphic features. Can J Neurol Sci 1992;19:243-5.
39. Carlsen NL. Neuroblastoma in denmark 1943-80. ACTA Paediatr Suppl 1994;403:1-27.
40. Stiller CA. Trends in neuroblastoma in Great Britain: incidence and mortality, 1971-1990. Eur J Cancer 1993;29A: 1008-12.
41. Van Hoff J, Schymura MJ, Curnen MG. Trends in the incidence of childhood and adolescent cancer in Connecticut, 1935-1979. Med Pediatr Oncol 1988;16:78-87.
42. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic types. Cancer 1995;75: 2186-95.
43. Gold E, Gordis L, Tonascia J, Szklo M. Risk factors of brain tumors in children. Am J Epidemiol 1979;109:309-19.
44. Spitz MR, Johnson CC. Neuroblastoma and parental occupation: a case-control analysis. Am J Epidemiol 1985;121: 927-8.
45. Savitz DA, Wachtel H, Barnes FA, John ME, Turdik JG. Case-control study of childhood cancer and exposure to 60-Mz magnetic fields. Am J Epidemiol 1987;128:21-8.
46. de Jong PCM, Huijsmans AA, Nienhuis HE, Nijdam WAS, Zielhuis GA, Eskes TKAB. Validation of a questionnaire on medical drug use during pregnancy. Am J Epidemiol 1991; 134:998-1002.
47. Werler MM, Pober BR, Nelson K, Holmes LB. Reporting accuracy among mothers of malformed and nonmalformed infants. Am J Epidemiol 1989;129:415-21.
48. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989;129:837-49.
49. Jones ME, Swerdlow AJ. Bias caused by migration in case-control studies of prenatal risk factors in childhood and adult diseases. Am J Epidemiol 1996;143:823-31.
50. U.S. Census and Population, 1980. Subject reports: geographical mobility for states in the nation (PC80-2-2A). Washington, DC: Government Printing Office, 1985.